Jump to content

Geoffrey von Maltzahn

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 12:46, 5 January 2021 (Alter: title. | You can use this bot yourself. Report bugs here. | Suggested by Abductive | Category:University of California, San Diego alumni | via #UCB_Category 124/527). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Geoffrey von Maltzahn
BornJuly 22, 1980
NationalityAmerican
Alma materMassachusetts Institute of Technology (S.B., 2003)
University of California, San Diego (M.S., 2005)
Massachusetts Institute of Technology (Ph.D. 2010)
Known forMicrobiome therapeutics, microbiome agriculture, communicating nanoparticles
AwardsLemelson-MIT Student Prize (2009)
National Inventors Hall of Fame Collegiate Inventors Competition Graduate Prize (2009),
Massachusetts Institute of Technology Randolph G Wei Award (2003)
Scientific career
FieldsMicrobiome, Microbiology, Nanotechnology, Microbiome Agriculture, Synthetic Biology
Academic advisorsSangeeta N. Bhatia, Shuguang Zhang

Geoffrey von Maltzahn, Ph.D. (born July 22, 1980) is an American biological engineer and entrepreneur in biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health and Tessera Therapeutics.[1][2][3] He has 200 bioengineering and biotechnology patents and applications.[4][5][6][7]

Early life and education

Geoffrey von Maltzahn was born in Arlington, Texas, and subsequently moved to Alexandria, Virginia where he graduated from Thomas Jefferson H.S. for Science and Technology. He was awarded his B.S. in Chemical Engineering from the Massachusetts Institute of Technology (MIT) in 2003, his Master of Science degree in Bioengineering from the University of California, San Diego in 2005, and his PhD from the Harvard–MIT Division of Health Sciences and Technology at the Massachusetts Institute of Technology in 2010.[8][9]

Career

Von Maltzahn is a general partner at Flagship Pioneering, a Massachusetts-based firm that creates start-ups in the healthcare and agriculture industries.[9] He joined in 2009, and focuses on inventing and building new life science companies. In the same year, he co-founded Axcella Health, a company focused on developing amino acid therapeutics. In 2010, he co-founded Seres Therapeutics[10] and served as the Chief Technology Officer.[11][12] In 2013, he co-founded Indigo Agriculture, a company focused on improving the microbiome of modern crops and is currently Chief Innovation Officer.[13] In 2015, he founded Kaleido Biosciences, is a clinical-stage biotechnology company engaged in the development of the microbiome. Until 2017, he served as the CEO of the company.

Awards and recognitions

See also

Indigo Agriculture
David Perry

References

  1. ^ Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine Business Insider Retrieved 9 October 2017
  2. ^ "Former Juno execs unveil Sana, a new cell engineering biotech that's reportedly raising more than $800M". GeekWire. January 7, 2019.
  3. ^ "This Company Wants to Rewrite the Future of Genetic Disease". Wired. July 7, 2020.
  4. ^ Patents by Inventor Geoffrey von Maltzahn Justia Patents
  5. ^ Patents as Early Indicators of Technology and Investment Trends Frontiers - figure 3 Retrieved 20 June 2018
  6. ^ Geoffrey von Maltzahn at Bloomberg Bloomberg
  7. ^ Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health Market Insider Retrieved 18 September 2017
  8. ^ Geoffrey von Maltzahn MIT
  9. ^ a b Geoffrey von Maltzahn at Bloomberg Bloomberg
  10. ^ Term Sheet Fortune Retrieved 21 July 2016
  11. ^ Seres Therapeutics IPO Soars, Raises $133 Million Investors Business Daily Retrieved 26 June 2015
  12. ^ Seres at Crunchbase Crunchbase
  13. ^ Indigo Agriculture on CNBC CNBC
  14. ^ "The under-40s: How does the next generation of biopharma executives view the future?". Endpoints. April 23, 2018.
  15. ^ "30 Under 40 Leaders in Biotech Pharma 2017". 2017-10-09. Retrieved 2017-10-09.
  16. ^ "MSNBC's Inventions of the Year". 2009-11-10. Retrieved 2017-10-09.